THE MUCOSAL SURFACES OF THE intestines, lined by columnar epithelial cells and interacting with trillions of microorganisms, are crucial sites of both innate and adaptive immune regulation. These cells exhibit numerous adaptations to maintain barrier function, including expression of tight junctions, actin-rich microvillar extensions, and secretion of a mucin and polysaccharide-rich glycocalyx (45) . Intestinal epithelial cells (IECs) further play an active role in innate immunity by expressing antimicrobial peptides, such as defensins, cathelicidins, and calprotectins (33) . Besides pattern-recognition receptors, another important innate sensing mechanism of host defense against bacteria in the gut is the complement system (17) . Downstream of the multiple routes to complement activation, the generation of C3 and C5 convertases are key reactions leading to the anaphylatoxins C3a and C5a, which are potent inflammatory mediators (43) . There is evidence from rodent models that C5a plays a mechanistic role during colonic disease. In rat trinitrobenzene sulfonic acid (TNBS)-induced colitis, C5a antagonist-treated rats showed significant improvements in their disease (55) . An anti-C5a antibody similarly provided a therapeutic benefit in TNBS colitis in mice (12) .
Finally, C5aR
Ϫ/Ϫ mice with dextran sodium sulphate-induced acute colitis demonstrated milder clinical symptoms and lower levels of cytokines during the course of this disease (28) .
Apart from experimental evidence for C5a playing a role during colitis, evidence for complement in the intestinal lumen is supported by reports showing local complement activation in the inflammatory bowel diseases (19, 24, 25, 30) , celiac disease, during Helicobacter pylori gastritis (9) , and following ischemia/reperfusion in the small intestine (21) . Collectively these studies indicate that complement activation is associated with worse disease. Finally, the membrane bound regulators decay-accelerating factor (DAF or CD55) and membrane inhibitor of reactive lysis (MIRL or CD59) are reportedly expressed on the apical surface of IECs (8, 51) , suggesting complement activation occurs in the lumen.
With the growing body of evidence for activated complement in the mucosa and a role for C5a in colitis, we asked whether IECs could detect and respond to complement activation. There are two heptahelical receptors known to bind C5a; C5a receptor (C5aR, CD88) and C5a receptor-like 2 (C5L2, GPR77). C5aR, initially appreciated to be expressed on myeloid cells such as mast cells, granulocytes, and monocytes/ macrophages, has now been reported to be widely expressed on nonimmune cells. The other receptor C5L2 shares 58% amino acid sequence homology with C5aR but is expressed at much lower levels on both immune and nonimmune cells and probably functions as a decoy receptor (31, 38) . As previous studies (15, 58) using in situ hybridization and immunohistochemistry failed to detect C5aR expression on IECs, we used alternative approaches to readdress this possibility. We report here our evidence that both receptors, C5aR and C5L2, are expressed apically on polarized colonic cell lines, indicating that human IECs are capable of detecting complement activation in the lumen. As a G-protein coupled receptor, C5aR stimulation is reported to activate multiple second messenger signaling systems (27, 44) . We show here that the key signaling pathway in eliciting an inflammatory phenotype in the IECs is ERK activation.
MATERIALS AND METHODS
Cell lines and cell culture. The human intestinal carcinoma cell line Caco2 was cultured in MEM supplemented with 10% (vol/vol) heatinactivated newborn calf serum, 2 mM L-glutamine, 1 nM nonessential amino acids, and 1 nM sodium pyruvate (all from Invitrogen, Grand Island, NY). Human T84 colonic carcinoma cells were cultured in DMEM/Ham's F-12 medium (1:1) supplemented with 5% (vol/vol) newborn calf serum and 2 mM L-glutamine (Invitrogen). Human HT29 colonic adenocarcinoma cells were cultured in MEM supplemented with 10% (vol/vol) heat-inactivated newborn calf serum, 2 mM L-glutamine, and 1 nM sodium pyruvate (all from GIBCO). Antibiotics (50 U/ml penicillin and 50 g/ml streptomycin) were added in all media. With ethical approval (Capital Health REB No. CDHA-RS/2003-121), anon-ymous, grossly normal-appearing margins of human colon resections for colon cancer were obtained and the crypt epithelium isolated according to the method published by Grossmann et al. (22) . The product of this technique is intact epithelium separated from the lamina propria. Total RNA was prepared from the crypt preparation. Polymorphonuclear leukocytes (PMN) RNA and protein were from samples recovered and enriched from healthy volunteers.
Reagents and antibodies. Mouse anti-human C5aR monoclonal antibody (clone S5/1) was purchased from GeneTex (GTX74846; Irvine, CA). Mouse anti-human C5L2 monoclonal antibody (clone 1D9) was described previously (6) and generously provided by Dr. Charles R. Mackay (Monash University, Melbourne, Victoria, Australia). Rabbit anti-human C5L2 antiserum was purchased from Abcam (Cambridge, MA). Mouse anti-human CD55 monoclonal antibody was purchased from Biolegend (clone JS11; San Diego, CA). Rabbit anti-human actin antiserum was purchased from Sigma (St. Louis, MO). Mouse IgG1 () and mouse IgG2a () isotype control antibodies were purchased from BD Biosciences (San Jose, CA). Alexa 488 conjugated goat anti-mouse IgG antiserum was purchased from Molecular Probes (Eugene, OR). Propidium iodide (10 g/ml) was purchased from Intergen (Burlington, MA). Recombinant human C5a was purchased from Sigma. In experiments in which inflamed mouse colons were incubated in complete media for 24 h, we calculated that roughly 10 nM C5a was detectable in the supernatants. We used this precedent to choose 10 nM as our starting concentration of C5a for experiments. Recombinant human TNF was purchased from Peprotech (Rocky Hill, NJ). Monoclonal antibodies used for Western Blot detection of pan-ERK and pERK1/2 were purchased from BD Biosciences (clone 16) and Santa Cruz (clone E4; Santa Cruz, CA), respectively. Horseradish peroxidase (HRP)-linked goat anti-mouse IgG antiserum was purchased from Sigma, and HRP-linked goat anti-rabbit IgG antiserum was purchased from Cell Signaling (Danvers, MA).
RT-PCR. RNA was extracted with TRIzol (Invitrogen) according to the manufacturer's protocol and stored frozen. One microgram of total RNA was denatured (95°C, 5 min) and then ice quenched (4°C, 5 min). Each sample had added to a final total volume of 20 l, dNTPs (5 mM), dithiothreitol (10 mM), random hexanucleotides (0.25 g), RNase/DNase free water, and 200 U moloney murine leukemia virus reverse transcriptase (Invitrogen) in RT buffer (final concentrations: 10 mM Tris·HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl 2, and 0.002% wt/vol gelatin). The reaction mixture was heated to room temperature (20°C) for 10 min and then incubated for 30 min at 42°C. The reaction was finally terminated by heating to 95°C. A negative control lacking RNA was also included to check for primer artifacts. Reactions using mRNA samples without adding RT were carried out to rule out contamination by genomic DNA. The conditions used for PCR were 1 min at 94°C, 1 min at 60°C, and then 1 min at 72°C for 25 cycles (actin) or 28 cycles (IL-8). The PCR products were separated on a 1.5% agarose gel impregnated with ethidium bromide. Primers for ␤-actin, C4, and CXCL8 (IL-8) have been published earlier (see Table 1 ). The deoxynucleotide primer sequences for factor B and C5aR were obtained from existing publications (2, 46) . Primers for C5 and C5L2 were designed from cDNA sequences (reference nos.: NM-001735.2 and NM-018485.1, respectively) using Primer Premier 5.0 software (Premier Biosoft International, Palo Alto, CA). Primers used to detect a 305-bp fragment from C5aR mRNA in Fig. 1B were as follows: sense, 5=-ATGCCATCTGGTTCCTCAAC-3=, antisense, 5=-GAAGG-AGGGTATGGTCAGCA-3=, otherwise, primer sequences used are listed in Table 1 .
Western blotting. T84, HT29, and Caco2 cells, some treated with C5a (10 nM) for 25 min, were lysed with M2 buffer containing protease and phosphatase inhibitor cocktails (P8340 and P5726; Sigma) to avoid catabolism of phosphorylated proteins. The M2 lysis buffer contained 0.5% NP-40, 20 mM ␤-glycerophosphate, 20 mM Tris base, 250 mM NaCl, 3 mM EDTA, and 3 mM EGTA, pH 7.5-8.0. Samples containing equal amounts of proteins were subjected to SDS-PAGE in 12% polyacrylamide gels. Separated proteins were electrotransferred to nitrocellulose membranes (Whatman Dassel, Germany), which were then were incubated at 4°C overnight with primary antibody. Membranes were washed four times with TBSTween and incubated with HRP-linked secondary antibody at room temperature for 1 h. ECL Western blotting detection reagents (Amersham, GE Healthcare, Buckinghamshire, UK) were added to the membrane, and films (Kodak, Burnaby, BC, Canada) were developed in an automatic film processor (SRX-101A; Konica Minolta, Tokyo, Japan). Protein loading was evaluated by reprobing membranes for ␤-actin after the bound antibodies were removed with a stripping buffer (62.5 mM Tris·HCl pH 6.8, 2% SDS, and 100 mM 2-mercaptoethanol) at 37°C for 60 min followed by blocking with skim milk.
Confocal microscopy. T84 and Caco2 cells were seeded at a confluent density onto polyester Transwell membranes, 6.5-mm diameter and 0.4-m pore size (Costar, Acton, MA), and grown in complete medium with daily medium changes before use. T84 cells were cultured for 7-8 days, and Caco2 cells were cultured for 21 days. In preparation for staining, the cells were washed three times with cold PBS and fixed with 4% paraformaldehyde for 10 min followed by an additional three washes with PBS. Then the cells were incubated with 7.5 g/ml propidium iodide for 15 min at room temperature. After three washes with PBS, cells were incubated for 2 h with blocking buffer (PBS containing 10% goat serum) at room temperature in the dark. The blocking buffer was then removed, and cells were washed twice with fresh PBS. Primary monoclonal antibodies (1 g/100 l PBS) against C5aR, C5L2, or CD55 were applied to cells in both apical and basolateral sides followed by an incubation at 4°C overnight in the dark. Isotype controls (mouse IgG1 , IgG2a ) were always included in parallel samples. After incubation, the cells were washed four times with PBS and stained with Alexa 488-conjugated goat anti-mouse antibody at 4°C for 60 min. Cells were then washed three times with PBS, mounted in Gold Prolonged Anti-Fade-Mounting-Reagents (Invitrogen), cured, sealed, and analyzed on a confocal laser microscope (LS 510 META, Zeiss, Germany) using the LS 510 META scanning software.
ELISA. A CXCL8 (IL-8) ELISA kit was purchased from Peprotech and used according to the manufacturer's instructions. The assays were developed with ABTS (Sigma). Absorbance readings were obtained at ϭ 405 nm/650 nm using an ELISA plate reader (SpectraMAX 190; Molecular Devices, Sunnyvale, CA). Sensitivity of the ELISA was 8 pg/ml for IL-8.
Permeability assay. Polarized T84 cells cultured on Transwells were treated for 24 h with C5a or IFN␥ (positive control). The ERK inhibitor PD98059 was added 30 min before the mediator treatment for some experiments. After the incubation, the monolayers were washed then had fresh media added for at least 45 min. Four kiloDalton dextran conjugated to fluorescein isothiocyanate (FITC-dextran) was added to the apical side at a final concentration of 3 mg/ml. After 3 h of incubation with the FITC conjugate, fluorescence of bottom chambers at 518 nm was measured by using a fluorometer (Thermo Scientific Fluoroskan Ascent FL; Thermo Fisher Scientific, Ottawa, ON). Data were expressed as (fluorescence of samples/ fluorescence of bare filter) ϫ 100%. Untreated cells on Transwells were used as a negative control. MTS assay for proliferation. Epithelial cell proliferation/viability was measured by using the colorimetric MTS [3-(4, 5- 
Ten thousand T84 cells were plated in 96-well tissue culture plates in complete medium and incubated for 72 h before treatment. Cells remained untreated or were treated with 100 ng/ml EGF as background and stimulated growth controls, respectively. The medium was refreshed containing the appropriate stimulus for a 24-or 48-h incubation after which 20 l CellTiter Aqueous One Solution (Promega) were added to each well, the plates incubated for an additional 3hr at 37°C in 5% CO 2, and subsequently the absorbance at 490 nm was assessed. Data were expressed by (OD 490 of samples/OD490 of nontreated cells) ϫ 100%, where OD490 is optical density at 490 nm.
Statistics. Data are presented as means Ϯ SD of replicates from a single representative experiment. Where there were more than two treatment groups, they were first tested using one-way ANOVA and if found significant, post hoc testing of groups was done using Tukey's test.
RESULTS

Complement and C5aRs are expressed by human colonic epithelium and cell lines.
In the course of our research studying human colonic epithelium as a source of inflammatory mediators, we examined a preparation (Fig. 1A) for C5 and the C5aR (Fig. 1B) . A positive mRNA signal was detected for both (Fig. 1B) , confirming published reports that the epithelium is a source of complement but also providing an early indication that the epithelium possessed receptors for C5a. We followed up this observation by first determining whether IEC lines also synthesized other representative complement molecules, as a surrogate for native epithelium. All three cell lines possess C4 and C5 mRNAs (Fig. 1C ) while T84 and HT29 possessed detectable factor B mRNA (Fig. 1D) . Then, using RT-PCR, we confirmed that all three IEC lines also possess mRNA for both C5aRs (Fig. 2, A and B) . Finally, using Western blotting we detected the proteins of the two receptors in the IECs (and PMN as a positive control, Fig. 2 , C and D; HT29 not shown). C5aR and C5L2 are expressed apically on IECs. As T84 and Caco2 polarize when grown on Transwell filters, we used this model to assess membrane/polarized C5aR expression. If anaphylatoxins are generated in the lumen, IECs would presumably express the receptor on the apical surface. As a control for apical expression we detected CD55 (8, 51) , shown in Fig. 3 , A and B, top The isotype control primary antibody consistently failed to stain the monolayers. Despite the addition of antibody to both sides of the filter, and similar to CD55, C5aR was detected exclusively on the apical surface of polarized Caco2 (Fig. 3A) . C5L2 localization was similar to C5aR with no expression basally (Fig. 3A) . Polarized T84 similarly express C5aR and C5L2 apically (Fig. 3B) .
C5a stimulation activates the ERK signaling pathway in IECs. Previous reports (10, 37, 42) indicated that MAPK signaling pathways could be activated by C5aR. We therefore conducted Western blots to detect the level of C5a-activated ERK (pERK), JNK (pJNK), and p38 (pp38) in the IEC lines. EGF was used as a positive control to detect pERK (Fig. 4) . The stimulation of IECs by C5a clearly upregulated the level of pERK1/2 (Fig. 4) but not pp38 or pJNK (data not shown).
C5a stimulation increases IL-8 levels in IECs. We speculated that if C5a has a role in stimulating inflammation it will likely elicit chemokine production by IECs. We chose to examine IL-8 (CXCL8) as it plays a key role in recruiting PMN, and interferon-inducible T-cell ␣-chemoattractant (ITAC; CXCL11) and regulated upon activation, normal T-cell expressed, and secreted (RANTES; CCL5) as representative mononuclear cell chemoattractants. Untreated IECs expressed low but detectable levels of IL-8 mRNA (Fig. 5, A and B) . We used TNF as a positive control for comparisons with C5a stimulated cells, and T84 and HT29 showed substantial increases in mRNA levels for IL-8 (Fig. 5, A and B) . TNF also stimulated a massive increase in the level of secreted IL-8 protein over 24 h of culture by HT29 and T84 but not Caco2 cells (Fig. 5C ). Consequently Caco2 cells were not further examined for cytokine responses. Despite substantial mRNA increases, levels of secreted IL-8 by C5a-treated T84 and HT29 cells only reached statistical significance after 48 h of incubation (Fig. 5D) . ITAC mRNA and protein changes followed the pattern observed with IL-8, e.g., high mRNA levels but relatively low protein levels in both cell lines (data not shown). RANTES, on the other hand, showed no response to C5a in any cell line. Now knowing that the cells respond to C5a with increased IL-8 mRNA levels, we further confirmed that activation of C5aR was limited to the apical membrane by adding C5a to the apical or basal chamber of polarized T84 and measured IL-8 3 . Confocal microscopic detection of C5aR and C5L2 expression on polarized IECs. Caco2 (A) and T84 (B) were cultured on Transwell filters for 21 and 7 days, respectively. Nuclei were stained using propidium iodide (red). Cells were stained with mouse anti-human CD55 (clone JS11) or mouse anti-human C5aR (clone S5/1) or mouse anti-human C5L2 (clone 1D9) primary antibody followed by Alexa 488 conjugated goat anti-mouse secondary antibody (green). Suitable isotype controls were included in every experiment and were consistently negative (IgG1 and IgG2a). Monolayers were observed using Z sections, which were compiled to form Z stacks. Images are representative Z stacks of three independent experiments. XY panels are images taken at apical surfaces, indicated as a white dashed line. Original magnification is ϫ400. One experiment representative of three is shown. mRNA as the readout. IL-8 mRNA levels were measured shortly after applying the C5a to detect the stimulus while the passive diffusion of C5a was minimal. We detected an increase in IL-8 mRNA early only when C5a was applied to the apical side of the cells (Fig. 6A) . Polarized T84 on Transwell filters stimulated apically with C5a secreted IL-8 mainly into the basal chamber but again did not show a significant increase compared with nontreated cells. As a positive control, basal treatment with TNF showed substantial and statistically significant IL-8 levels in both chambers with the greatest amount of protein in the basal chamber (Fig. 6B) . In view of the low secreted IL-8 levels, we addressed the question of whether cells sequestered the IL-8 protein in the cytoplasm in C5a-treated cells by preparing cell lysates with nondenaturing M2 lysis buffer and conducted ELISAs. No significant levels of intracellular IL-8 were observed (data not shown). The possibility of a false negative finding measuring intracellular cytokines was controlled by spiking human IL-8 protein into lysis buffer as positive control.
Despite a clear increase in IL-8 mRNA levels, the increase in secreted IL-8 protein was very low compared with the levels achieved using TNF (Fig. 5) . We speculated that a second signal may be required to heighten message translation stimulated by C5a, so we combined C5a with LPS. LPS is a ligand for Toll-like receptor-4 (TLR4), which signals through MyD88-dependent and -independent pathways as well as through NF-B. T84 cells stimulated with 1 g/ml LPS for 24 h showed significantly increased secretion of IL-8 protein (albeit still lower than stimulated by TNF). The combination of C5a and LPS did not show any further upregulation of IL-8 secretion; in fact, C5a appeared to prevent the increase induced by LPS (not shown).
C5a stimulation of IL-8 is ERK dependent.
We showed earlier that IECs had detectable levels of pERK, which were enhanced following the addition of C5a. Treating the cells with PD98059, an ERK activation inhibitor, before adding C5a blocked the increase in pERK (Fig. 7A) . PD98059 also blocked ERK activation following exposure to EGF (not shown). To investigate whether the increase in ERK phosphorylation is mechanistically linked with the chemokine mRNA regulation, cells were stimulated in the presence of PD98059. With ERK activation blocked, the IECs failed to increase the level of IL-8 mRNA in response to C5a (Fig. 7B) . EGF, while increasing pERK, did not stimulate increased IL-8 mRNA (shown for T84 in Fig. 7B ). This means that ERK activation while necessary is not sufficient for chemokine mRNA upregulation due to C5a.
ERK signaling is critical for C5a-mediated increases in monolayer permeability. The barrier role is a key function of intestinal epithelium and inflammation often compromises this barrier. To investigate the effect of C5a stimulation on IEC barrier function, we conducted a permeability assay dependent on diffusion of FITC-dextran (4 kDa) through the polarized cell monolayer. IFN␥, used as a positive control, is known to increase monolayer permeability and barrier dysfunction (4, 34) . T84 monolayers treated with 50 ng/ml IFN␥ for 24 h showed a fourfold increase in permeability when compared with nontreated monolayers (Fig. 8) . Then, compared with the level of diffusion across intact monolayers, treating with 10 nM or 100 nM C5a for 24 h increased the permeability by 2.6-and 3.1-fold, respectively (Fig. 8) , indicating C5aR activation by C5a has an impact on IEC barrier function. Since we already showed that C5aR stimulation activates ERK signaling, we determined whether the ERK activation was involved in the C5a-induced increase in permeability. After blocking with PD98059, the permeability of 10 or 100 nM C5a-treated monolayers remained at levels comparable to that of nontreated cells (Fig. 8) . Thus ERK activation is critical in C5a-mediated IEC monolayer barrier dysfunction, as shown by increased paracellular permeability.
C5a-stimulated IEC proliferation is dependent on the ERK pathway. During inflammation, IECs are likely stimulated to proliferate to balance cell loss and ERK activation is commonly involved in cell survival and proliferation. Thus we examined the possibility that C5a also has an impact on cell proliferation, acting through ERK. At low confluence, C5a-treated T84 and HT29 both showed increased proliferation/ Fig. 8 . C5a increases T84 monolayer permeability and requires ERK activation. T84 cells were cultured in Transwells for 7-8 days in complete medium then C5a was applied apically to the monolayer for 24 h. IFN␥ at 50 ng/ml was applied basally for 24 h, as a positive control for increasing monolayer permeability. For blocking ERK activation, 5 M PD98059 was applied apically for 30 min before treatments and DMSO was used as diluent control. Four kD dextran conjugated to fluorescein isothiocyanate was added to the apical side at a final concentration of 3 mg/ml. After a 3-h incubation, fluorescence at 518 nm was measured in the basolateral compartment. Data are expressed as (fluorescence of samples/fluorescence of bare filter) ϫ 100%. *P Ͻ 0.05. One experiment representative of four is shown. Fig. 9 . ERK activation is required for increased IEC proliferation due to C5a. Cells remained untreated or were treated with 100 ng/ml EGF as background and stimulated growth controls, respectively. The medium was refreshed containing the indicated stimulus for a 24 or 48 h incubation. survival (Fig. 9) . The increase induced by C5a was comparable to EGF-treated T84 (Fig. 9A) . Applying PD98059 to block the ERK pathway before C5a stimulation or EGF treatment significantly arrested the proliferation/survival (Fig. 9) . We conclude from these data that C5a acting through the C5aR provides a proliferation/survival signal that is dependent on ERK activation C5L2 antagonizes the C5aR response to C5a. The role of C5L2 in most cell types remains unclear but much of the evidence favors it acting as an antagonist to C5aR. To gain some insights into what effect C5L2 may have on C5a triggering an increase in IL-8 in IECs, we applied a C5L2 function-blocking antibody to the cultures before adding C5a. Figure 10 shows that blocking C5L2 resulted in 24-h levels of secreted IL-8 greater than levels achieved in the absence of control antibody, indicating that C5L2 antagonizes the C5aR by this measure.
DISCUSSION
Complement activation protects against invading microorganisms but whether this occurs in the gut lumen has not been unequivocally demonstrated. Considering the large numbers of bacteria resident in the healthy gut, complement may be active in limiting the sites along the gut that become colonized. Moreover, it is clear that complement becomes activated and contributes to colitis in the colon (8, 23, 30, 50, 51) . We have focused our research on the possible contribution to, and interactions of, epithelial cells with complement. First, our data showing all three IEC lines (T84, Caco2, and HT29) express mRNA for complement glycoproteins are consistent with reports of C4 expression at the protein level in T84 and Caco2 and factor B detected in Caco2 cell culture supernatants, confirming that IECs are a source of complement in the gut (5, 7) . Secondly, we are interested to know whether IECs can detect activated complement, as an alarm signal. Among the late effectors generated by complement activation, the anaphylatoxin C5a is a potent molecule that elicits a broad range of proinflammatory activities, and we sought whether IECs possess the C5aR. Collectively, our results demonstrate that C5a provokes an "inflammatory" response through apical C5aR on model colonic epithelium. Moreover, multiple outcomes share a point of convergence along the ERK signaling pathway (Fig. 11) . One constraint, however, is the relatively conservative levels of secreted chemokine, which we interpret to indicate that a second signal is necessary to fully activate the translational machinery, a hypothesis that we are exploring further.
The activities of human C5a are induced by binding to the specific, high-affinity C5aR (CD88), which belongs to the superfamily of G-protein-coupled seven transmembrane spanning receptors (40) . C5aR, initially thought to be present mainly on leukocytes and most abundantly in cells of the myeloid lineage (29), appears to be expressed in many nonhematopoietic cell types including the epithelia of kidney and lung (1, 14, 16, 26, 41, 54) , suggesting new physiological roles. However, studies on normal human intestine using mAbs P12/1 and D12/1 by Fayyazi and colleagues (15, 58) failed to detect IEC expression. This negative outcome could be due to interference by mucus or the glycocalyx or sampling along the length of the intestine. It is possible that expression is upregulated during inflammation. Despite this precedent, the accumu- IEC lines were cultured in complete medium in 6-well plates. C5L2 blocking antibody, clone 1D9, was applied at a concentration of 5 g/ml in the culture 30 min before the C5a treatment. Control cell cultures were treated using the same concentration of mouse IgG2a () control antibody. Cells were treated with C5a for 24 h and secreted IL-8 was determined by ELISA. One experiment representative of three is shown. *P value Ͻ0.05.
lating evidence pointing to complement activation on the intestinal mucosa (19, 24, 30, 50) along with our result detecting C5aR mRNA in human colon crypt epithelial cells, was impetus for us to reexamine model colonic epithelial cells for the receptors. Moreover, reports proposed that IECs are poor responders to TLR ligands due to their negligible expression of TLR4 and CD14 (3, 35) and restricted basolateral expression of TLR5 (20) . These facts also support the possibility that IECs might detect the anaphylatoxins and therefore presumably would indirectly detect bacteria that have activated complement as an alarm signal at the luminal surface. Indeed, we show apical expression of C5aR and C5L2 on both human colonic epithelial cell lines that grow polarized.
Signaling through C5aR has been studied in greater detail in myeloid cells, with less known about signaling in nonhematopoietic cells. Apart from Ca 2ϩ changes, the signaling cascade can lead to activation of ERK1/2 in endothelial cells (36) and Akt (27, 44) . Our results indicate that stimulation of the C5aR in all three IEC lines results in the activation of ERK1/2. Interestingly, the blockade of ERK activation by the inhibitor PD98059 resulted in not only the inhibition of ERK activation but also blocked the increase in IL-8 mRNA levels, directly implicating ERK in the IL-8 mRNA increase. While EGF likewise activated ERK, there was no apparent change in the levels of IL-8 mRNA. We therefore conclude that ERK is necessary but not sufficient for IEC upregulation of chemokine mRNA in response to C5a. Regarding candidate second signals that may cooperate with ERK to result in increased IL-8 mRNA, we ruled out other MAPK based on Western blots of pJNK, pp38 not increasing. We combined a low concentration of LPS, which signals through multiple pathways including MAPK and NF-B, but this did not synergize with C5a to result in greater levels of secreted protein. We are presently determining the state of the message and whether it is available for greater translation.
Besides C5aR, C5L2 was also detected on the apical membrane of polarized IECs. C5L2 is considered to be a decoy receptor as it does not bind G proteins. In our study, blocking C5L2 with a specific mAb before C5a stimulation showed a statistically significant enhancement in IL-8 secretion over 24 h in both T84 and HT29. The simple explanation is that the blockade of C5aR increased the local concentration of C5a. Yet, blocking C5L2 may also decrease the otherwise rapid internalization of the ligand-bound receptor, thereby possibly impacting downstream signaling events shared with C5aR activation, for example, through transactivation of certain receptor tyrosine kinases (13) .
Regarding the impact of C5a on epithelial cells, there are precedents for anaphylatoxin-stimulated cytokine or chemokine production in other treated epithelia. Stimulation of human retinal pigment epithelial cells with C5a induced a doseand time-dependent increase of IL-8 mRNA expression, but protein levels were not assessed (18) . Rat alveolar epithelial cells treated with C5a did not show any significant change in the levels of proinflammatory mediators unless the cells were preexposed to LPS, IL-6, or TNF (39) . Our study demonstrates that C5a-treated T84 and HT29 cells both increase levels of IL-8 (and ITAC) mRNA within hours of the treatment; however, a significant increase in the level of IL-8 was only achieved after 48 h. It is possible that more time may be necessary to achieve higher levels, which, however, is not the case with TNF-induced expression.
Another important role of IECs is as a barrier, made possible due to intercellular tight junctions that restrict the paracellular diffusion of proteins and lipids (49, 52) . Epithelial barrier dysfunction is an underlying cause of several pathological conditions. Whether this barrier function change is associated with activation of the complement system, release of C5a, and interactions between C5a-C5aR in IECs is unknown. Our permeability data using diffusion of 4-kDa FITC-dextran showed up to a threefold increase in permeability after 24-h treatment with C5a compared with nontreated monolayers, indicating the IEC barrier was disturbed. Blocking the ERK pathway with PD98059 before C5a stimulation protected the monolayer integrity. Studies on the role of ERK in the regulation of epithelial integrity have produced mixed results. ERK1/2 activation was reported to inhibit claudin-2 expression and transiently increase tight junction integrity in Madin-Darby canine kidney strain I and II cells (32) . This process was blocked by the MAPK/ERK kinase inhibitor U0126. A second study (53) showed that activation of PKC disrupts tight junctions by a MAPK-dependent mechanism. Another study (56) showed that bile in the intestinal lumen initiates ERK1/2-dependent signaling that is essential for normal expression of key tight junction proteins and regulation of epithelial integrity. These contrasting results pose a challenge in defining the precise role of ERK in regulation of intestinal integrity. C5aR signaling is critical to the disruption of integrity of our T84 monolayers; whether or not cross talk with other signaling pathways is also contributing still needs to be determined.
Interventions aimed at blocking complement including C5a/ C5aR signaling represent promising targets for therapeutic treatment of inflammatory disorders. Systemic administration of C5aR-specific small interfering RNA is capable of reducing C5aR gene expression in vivo and was shown to prevent ischemia/reperfusion injury of kidney and lung (47, 48, 57) . Blockade of the C5aR demonstrated protective effects in TNBS-induced colitis in rats (55) and using a specific antiserum to block C5a had therapeutic effects on TNBS-induced colitis in mice (11) . Although the activation of complement components may be strictly limited under normal conditions in the gut, complement activation most certainly has an impact on diseases of the gastrointestinal tract. Our findings that IECs express C5aR apically and directly respond to C5a through ERK signaling pathway with responses that promote inflammation further highlight the multipotent activities of anaphylatoxins in gastrointestinal disease.
